Home > Oncology > SABCS 2022 > Early-Stage Breast Cancer > MammaPrint test predictive for benefit of extended endocrine therapy

MammaPrint test predictive for benefit of extended endocrine therapy

Presented By
Dr Laura van ‘t Veer, UCLA, CA, USA
Conference
SABCS 2022
Trial
Phase 3, IDEAL
Doi
https://doi.org/10.55788/9a93a95b
In addition to predicting the benefit of adjuvant chemotherapy in patients with early breast cancer, the 70-gene MammaPrint test also predicts who benefits from extended endocrine therapy, results from the IDEAL and NSABP-B42 trials showed. Previously, the MINDACT study (NCT00433589) showed that the 70-gene MammaPrint test is able to predict the benefit of adjuvant chemotherapy in patients with early breast cancer [1,2]. ER-positive patients with a MammaPrint low-risk score do not benefit from adjuvant chemotherapy and are thus preferably treated with an extended endocrine therapy. However, some low-risk patients may be more likely to derive benefits from extended endocrine therapy than others, depending on their risk of late recurrence. Therefore, genomic classifiers that predict the risks of late recurrence may assist with treatment decisions. I...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on